133 related articles for article (PubMed ID: 30981510)
21. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
[TBL] [Abstract][Full Text] [Related]
22. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells.
Ikeda K; Saito T; Tojo K
Tohoku J Exp Med; 2011 Aug; 224(4):263-71. PubMed ID: 21757861
[TBL] [Abstract][Full Text] [Related]
23. Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts.
Lei B; Hitomi H; Mori T; Nagai Y; Deguchi K; Mori H; Masaki T; Nakano D; Kobori H; Kitaura Y; Nishiyama A
J Pharmacol Sci; 2011; 117(2):98-105. PubMed ID: 21897055
[TBL] [Abstract][Full Text] [Related]
24. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates Ca2+ influx in brain vascular smooth muscle cells.
Matsuoka T; Nishizaki T; Nomura T
Biochem Biophys Res Commun; 1997 Nov; 240(2):484-7. PubMed ID: 9388505
[TBL] [Abstract][Full Text] [Related]
25. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers.
Okayama S; Imagawa K; Naya N; Iwama H; Somekawa S; Kawata H; Horii M; Nakajima T; Uemura S; Saito Y
Hypertens Res; 2006 Jul; 29(7):493-7. PubMed ID: 17044661
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect.
Masumiya H; Shijuku T; Tanaka H; Shigenobu K
Eur J Pharmacol; 1998 May; 349(2-3):351-7. PubMed ID: 9671117
[TBL] [Abstract][Full Text] [Related]
27. Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development.
Tanaka H; Shigenobu K
J Pharmacol Sci; 2005 Nov; 99(3):214-20. PubMed ID: 16293935
[TBL] [Abstract][Full Text] [Related]
28. Species difference in the contribution of T-type calcium current to cardiac pacemaking as revealed by r(-)-efonidipine.
Tanaka H; Komikado C; Namekata I; Nakamura H; Suzuki M; Tsuneoka Y; Shigenobu K; Takahara A
J Pharmacol Sci; 2008 May; 107(1):99-102. PubMed ID: 18460822
[TBL] [Abstract][Full Text] [Related]
29. [Effect of efonidipine hydrochloride on myocardial oxygen balance in anesthetized dogs].
Fujikura N; Yokoyama T; Masuda Y; Shikada K; Tanaka S
Nihon Yakurigaku Zasshi; 1996 Aug; 108(2):39-48. PubMed ID: 8827722
[TBL] [Abstract][Full Text] [Related]
30. Possible requirement of phosphonate moiety for efonidipine effects on the sino-atrial node action potential.
Masumiya H; Matsuda T; Tanaka Y; Tanaka H; Shigenobu K
Life Sci; 2000; 66(16):PL239-44. PubMed ID: 10794505
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.
Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M
Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577
[TBL] [Abstract][Full Text] [Related]
32. Vascular effects of calcium channel antagonists: new evidence.
Richard S
Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
[TBL] [Abstract][Full Text] [Related]
33. Effects of efonidipine hydrochloride on renal arteriolar diameters in spontaneously hypertensive rats.
Nakamura M; Notoya M; Kohda Y; Yamashita J; Takashita Y; Gemba M
Hypertens Res; 2002 Sep; 25(5):751-5. PubMed ID: 12452329
[TBL] [Abstract][Full Text] [Related]
34. Divergent action of calcium channel blockers on ATP-binding cassette protein expression.
Hasegawa K; Wakino S; Kanda T; Yoshioka K; Tatematsu S; Homma K; Takamatsu I; Sugano N; Hayashi K
J Cardiovasc Pharmacol; 2005 Dec; 46(6):787-93. PubMed ID: 16306803
[TBL] [Abstract][Full Text] [Related]
35. Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.
Ohashi N; Mitamura H; Ogawa S
Drugs; 2009; 69(1):21-30. PubMed ID: 19192934
[TBL] [Abstract][Full Text] [Related]
36. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters.
Suzuki S; Ohkusa T; Ono K; Sato T; Yoshida MA; Yano M; Takebayashi S; Matsuzaki M
Circ J; 2007 Dec; 71(12):1970-6. PubMed ID: 18037756
[TBL] [Abstract][Full Text] [Related]
38. [Effect of efonidipine hydrochloride (NZ-105), a dihydropyridine derivative with calcium antagonistic action, on myocardial oxygen tension in anesthetized dogs].
Fujikura N; Yokoyama T; Masuda Y; Shikada K; Tanaka S
Nihon Yakurigaku Zasshi; 1996 Nov; 108(5):267-74. PubMed ID: 8974087
[TBL] [Abstract][Full Text] [Related]
39. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis.
Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Ozawa Y; Saruta T
Clin Sci (Lond); 2001 Oct; 101(4):421-7. PubMed ID: 11566080
[TBL] [Abstract][Full Text] [Related]
40. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats.
Fujiwara K; Kanno Y; Hayashi K; Takenaka T; Saruta T
Clin Exp Hypertens; 1998 Apr; 20(3):295-312. PubMed ID: 9605384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
